Pandemic Leads to Delays in Crucial Early Cancer Screening Tests
Clayton Lau, MD, discusses the consequences of patients delaying cancer screenings due to fears of COVID-19.
Clayton Lau, MD, discusses the consequences of patients delaying cancer screenings due to fears of COVID-19.
A recent article pointed out that efforts to decrease low-value care often fall short. It asserted that a primary cause is physicians being financially motivated.
Acalabrutinib plus bendamustine and rituximab bettered progression-free survival over bendamustine and rituximab alone in patients with untreated mantle cell lymphoma.
Administering high-intensity focused ultrasound could be a noninferior treatment option for patients with localized prostate cancer, according to a prospective trial.
Mark D. Tyson, II, MD, MPH, discusses the background of the phase 3 BOND-003 study evaluating cretostimogene grenadenorepvec in patients with high-risk Bacillus Calmette-Guérin-unresponsive non-muscle-invasive…
Apalutamide with androgen deprivation therapy following radical prostatectomy led to a biochemical recurrence-free survival rate of 100% after 2 years among patients with high-risk prostate…
In the phase 3 BOND-003 trial, cretostimogene grenadenorepvec led to durable complete responses over 12 months among patients with high-risk BCG-unresponsive non-muscle-invasive bladder cancer with…
In separate, live virtual events, Arnab Basu, MD, MPH, and Robert J. Motzer, MD, asked participants which therapy they would choose for a patient with…
Major gaps in breast, cervical, and colorectal cancer screening use in federally qualified health centers in the United States were seen compared with overall screening…
In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.
With an FDA orphan drug designation now granted to IGNK001, clinical trials investigating the agent in acute myeloid leukemia are planned to initiate in the…